|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RWDD4 |
Gene summary for RWDD4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RWDD4 | Gene ID | 201965 |
| Gene name | RWD domain containing 4 | |
| Gene Alias | FAM28A | |
| Cytomap | 4q35.1 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | E7EV43 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 201965 | RWDD4 | LZE4T | Human | Esophagus | ESCC | 1.79e-13 | 3.39e-01 | 0.0811 |
| 201965 | RWDD4 | LZE7T | Human | Esophagus | ESCC | 1.46e-06 | 3.70e-01 | 0.0667 |
| 201965 | RWDD4 | LZE8T | Human | Esophagus | ESCC | 2.29e-05 | 1.57e-01 | 0.067 |
| 201965 | RWDD4 | LZE20T | Human | Esophagus | ESCC | 6.20e-03 | 2.15e-01 | 0.0662 |
| 201965 | RWDD4 | LZE22T | Human | Esophagus | ESCC | 3.23e-03 | 4.38e-01 | 0.068 |
| 201965 | RWDD4 | LZE24T | Human | Esophagus | ESCC | 2.22e-17 | 5.11e-01 | 0.0596 |
| 201965 | RWDD4 | LZE6T | Human | Esophagus | ESCC | 5.77e-05 | 3.88e-01 | 0.0845 |
| 201965 | RWDD4 | P1T-E | Human | Esophagus | ESCC | 2.55e-06 | 2.89e-01 | 0.0875 |
| 201965 | RWDD4 | P2T-E | Human | Esophagus | ESCC | 1.70e-36 | 6.66e-01 | 0.1177 |
| 201965 | RWDD4 | P4T-E | Human | Esophagus | ESCC | 1.12e-31 | 8.82e-01 | 0.1323 |
| 201965 | RWDD4 | P5T-E | Human | Esophagus | ESCC | 3.30e-43 | 8.04e-01 | 0.1327 |
| 201965 | RWDD4 | P8T-E | Human | Esophagus | ESCC | 8.26e-19 | 3.47e-01 | 0.0889 |
| 201965 | RWDD4 | P9T-E | Human | Esophagus | ESCC | 1.85e-10 | 3.81e-01 | 0.1131 |
| 201965 | RWDD4 | P10T-E | Human | Esophagus | ESCC | 1.76e-21 | 3.17e-01 | 0.116 |
| 201965 | RWDD4 | P11T-E | Human | Esophagus | ESCC | 1.22e-10 | 4.74e-01 | 0.1426 |
| 201965 | RWDD4 | P12T-E | Human | Esophagus | ESCC | 7.63e-48 | 9.27e-01 | 0.1122 |
| 201965 | RWDD4 | P15T-E | Human | Esophagus | ESCC | 7.37e-28 | 6.53e-01 | 0.1149 |
| 201965 | RWDD4 | P16T-E | Human | Esophagus | ESCC | 3.24e-40 | 6.29e-01 | 0.1153 |
| 201965 | RWDD4 | P17T-E | Human | Esophagus | ESCC | 1.15e-16 | 6.49e-01 | 0.1278 |
| 201965 | RWDD4 | P19T-E | Human | Esophagus | ESCC | 4.06e-05 | 5.22e-01 | 0.1662 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RWDD4 | SNV | Missense_Mutation | c.92C>A | p.Ser31Tyr | p.S31Y | Q6NW29 | protein_coding | deleterious(0.01) | possibly_damaging(0.837) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RWDD4 | insertion | Frame_Shift_Ins | novel | c.204_205insT | p.Asn69Ter | p.N69* | Q6NW29 | protein_coding | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| RWDD4 | SNV | Missense_Mutation | novel | c.376A>G | p.Asn126Asp | p.N126D | Q6NW29 | protein_coding | tolerated(0.47) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RWDD4 | SNV | Missense_Mutation | novel | c.296C>T | p.Thr99Ile | p.T99I | Q6NW29 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RWDD4 | SNV | Missense_Mutation | novel | c.427N>T | p.Asp143Tyr | p.D143Y | Q6NW29 | protein_coding | deleterious(0.01) | benign(0.44) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RWDD4 | SNV | Missense_Mutation | novel | c.517G>A | p.Val173Ile | p.V173I | Q6NW29 | protein_coding | tolerated(0.06) | benign(0.236) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| RWDD4 | SNV | Missense_Mutation | rs752249282 | c.461N>A | p.Arg154His | p.R154H | Q6NW29 | protein_coding | deleterious(0) | possibly_damaging(0.877) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| RWDD4 | SNV | Missense_Mutation | novel | c.163N>C | p.Tyr55His | p.Y55H | Q6NW29 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EY-A5W2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RWDD4 | SNV | Missense_Mutation | novel | c.428N>G | p.Asp143Gly | p.D143G | Q6NW29 | protein_coding | tolerated(0.06) | benign(0.075) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| RWDD4 | insertion | Frame_Shift_Ins | novel | c.204dupT | p.Asn69Ter | p.N69* | Q6NW29 | protein_coding | TCGA-BS-A0UM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |